Advanced Solid Tumors Clinical Trial
Official title:
A Phase I, Open-Label Study to Investigate the Tolerability and Safety of IBI310 Alone or in Combination With Sintilimab in the Treatment of Patients With Advanced Solid Tumors.
Verified date | February 2023 |
Source | Innovent Biologics (Suzhou) Co. Ltd. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is an open-label, dose escalation, Phase I study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and efficacy of single agent of IBI310, and in combination of sintilimab, in patients with advanced solid tumors(Ia) and advanced melanoma(Ib).
Status | Completed |
Enrollment | 53 |
Est. completion date | August 9, 2022 |
Est. primary completion date | September 10, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Key Inclusion Criteria: 1. Patients with locally advanced, recurrent or metastatic solid tumors who failed standard treatment(applicable to the Ia period). 2. Patients with advanced, recurrent or metastatic melanoma confirmed by cytology or histology (applicable to the Ib period). 3. Signed written informed consent form and willing and able to comply with scheduled visits and other requirements of the study. 4. =18,and =70 years. 5. Life expectancy of at least 12 weeks. 6. At least 1 measurable lesion per RECIST v1.1(long axis>15mm or short axis>10mm) 7. Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-1. 8. Patients of reproductive potential must be willing to use adequate contraception during the course of the study and through 6 months after the last dose of study medication. 9. Adequate organ and bone marrow function. Key Exclusion Criteria: 1. Prior exposure to any anti-CTLA-4, anti-PD-1 or anti-PD-L1/L2 antibody. 2. Received any investigational agent within 4 weeks of the first dose of study medication. 3. Received last dose of anti-tumor therapy (chemotherapy, endocrine therapy, targeted therapy, tumor immunotherapy or arterial embolization) within 4 weeks of the first dose of study medication. 4. Received treatment with corticosteroids (>10mg daily prednisone equivalent) or other immunosuppressive medications within 4 weeks before the first dose of study medication. Nasal spray, inhalation, or other ways of topical corticosteroids or physiological doses of systemic corticosteroids are not included. 5. Received a live vaccine within 4 weeks of the first dose of study medication or plan to receive live vaccine during study period. 6. Active, known or suspected autoimmune disease or has a history of the disease within the last 2 years (Patients with vitiligo, psoriasis, alopecia or Grave's disease, hypothyroidism requiring hormone replacement, or type I diabetes mellitus only requiring insulin replacement, but not required systemic treatment in the last 2 years, are permitted to enroll) 7. Known primary immunodeficiency 8. Active tuberculosis 9. Known history of allogeneic organ or allogeneic hemopoietic stem cell transplantation 10. Known allergy or hypersensitivity to any other monoclonal antibodies or IBI310 and/or any components used in their preparation. 11. Known acute or chronic active hepatitis B (HBV DNA positive and HBV DNA copies =1×103/ml or =200IU/ml) infection or acute or chronic active hepatitis C (HCV antibody positive and HCV RNA positive) infection. Patients with HCV antibody positive but HCV RNA negative are permitted to enroll. 12. Patients with a history of interstitial lung disease 13. Uncontrolled third space effusion, eg. ascites or pleural effusion cannot be drained or controlled. 14. Women who are pregnant or nursing. |
Country | Name | City | State |
---|---|---|---|
China | Beijing Cancer Hospital | Beijing | Beijing |
Lead Sponsor | Collaborator |
---|---|
Innovent Biologics (Suzhou) Co. Ltd. |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | AEs | Number of patients with treatment-related adverse events (AEs) | up to 24 months after randomization | |
Secondary | Pharmacokinetics:Cmax | Maximum concentration(Cmax) of the drug after administration | up to 24 months after randomization | |
Secondary | pharmacodynamics:lipid parameters | Change from baseline in lipid parameters | up to 24 months after randomization | |
Secondary | ADA | Number of participants with anti-drug antibodies or neutralizing antibodies | up to 24 months after randomization | |
Secondary | Pharmacokinetics:AUC | The area under the curve (AUC) of serum concentration of the drug after the administration | up to 24 months after randomization |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04972981 -
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT05086822 -
A Study of Irinotecan Hydrochloride Liposome in Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT03260322 -
A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Recruiting |
NCT06040541 -
Study of RMC-9805 in Participants With KRASG12D-Mutant Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05862831 -
Clinical Study of PM1003 in Phase I/IIa Treatment of Advanced Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03641794 -
Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Healthy Volunteers
|
Phase 1 | |
Terminated |
NCT03665129 -
IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors
|
Phase 1 | |
Not yet recruiting |
NCT06413680 -
A First-In Human (FIH) Trial to Find Out if REGN10597 is Safe and How Well it Works for Adult Participants With Advanced Solid Organ Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05914116 -
A Study of DB-1311 in Advanced/Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT01693562 -
A Phase 1/2 Study to Evaluate MEDI4736
|
Phase 1/Phase 2 | |
Recruiting |
NCT04387916 -
A Study of KC1036 in Patients With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT04095273 -
Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug
|
Phase 1 | |
Not yet recruiting |
NCT03692520 -
Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SCT200 in Patients With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT02997176 -
An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800)
|
Phase 1 | |
Recruiting |
NCT04446260 -
A Study of SHR-A1811 in Subjects With Advanced Malignant Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06239155 -
A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT02253992 -
An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT06076291 -
An Open-label Study of SG1827 in Subjects With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT00962091 -
Study of MLN8237 in Participants With Advanced Solid Tumors
|
Phase 1 |